Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 Next >
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Third Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Acquire Cernostics
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Second Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the DERM2021 NP/PA CME Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Collaborates with the Melanoma Research Foundation
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Participate at the Canaccord Genuity 41st Annual Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Expands its Board of Directors with New Appointments
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences is Listed in the Houston Chronicle’s “CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Receipt of New York Laboratory Permit
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Participate at the Baird 2021 Healthcare ESG Symposium
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.